ERBB2 and breast carcinoma: In a BROCADE 3 phase III randomized, placebo-controlled clinical trial, veliparib in combination with carboplatin and paclitaxel showed significant improvement in PFS (14.5 months vs. 12.6 months, p = 0.0016) in patients with BRCA mutation-associated HER2-negative advanced breast cancer [30].